Effectiveness and safety of once‐weekly subcutaneous semaglutide versus other glucose‐lowering agents in real‐world patients with type 2 diabetes: A retrospective, observational post‐marketing study
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15552 ↗Kurz gefasst
Leserbrief in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Chenyang Shi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glucagon-Like Peptides. Die Arbeit nennt 13 Literaturangaben. Gefördert von: Shanghai Pharmaceutical Association of Clinical Comprehensive Evaluation of Drugs and Research Project on Drug Treatment Pathways.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China.
- Department of Military Health Statistics, Naval Medical University, Shanghai, China.
- Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China.
ORCID-Profile: Chenyang Shi
Förderung
- Shanghai Pharmaceutical Association of Clinical Comprehensive Evaluation of Drugs and Research Project on Drug Treatment Pathways
Zitieren
APA
Shi, C., Tan, Y., Hu, S., Qin, Y., Tang, Y., Wang, Y., & Fan, G. (2024). Effectiveness and safety of once‐weekly subcutaneous semaglutide versus other glucose‐lowering agents in real‐world patients with type 2 diabetes: A retrospective, observational post‐marketing study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15552
Vancouver
Shi C, Tan Y, Hu S, Qin Y, Tang Y, Wang Y, et al. Effectiveness and safety of once‐weekly subcutaneous semaglutide versus other glucose‐lowering agents in real‐world patients with type 2 diabetes: A retrospective, observational post‐marketing study. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15552
BibTeX
@article{Shi2024,
author = {Shi, Chenyang and Tan, Yijiong and Hu, Shanshan and Qin, Yingyi and Tang, Yuanjun and Wang, Yufan and Fan, Guorong},
title = {Effectiveness and safety of once‐weekly subcutaneous semaglutide versus other glucose‐lowering agents in real‐world patients with type 2 diabetes: A retrospective, observational post‐marketing study},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15552}
}
EUVIMED